Health

Results: 5437-5448 of 8803

The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he found the lost sheep, our joy knew no bounds, when we got encouraging outcome in DMD research. Now on receiving orphan drug and rare paediatric disease designations from US FDA, while it’s time to rejoice, we have miles to go until it reaches every deserving patient after an approval, the final goal. We are open to collaborate with likeminded institutes to reach the goal. Further insights have revealed the potentials of Neu REFIX in Psoriasis, auto-immune diseases and in Multiple Sclerosis by gut microbiome reconstitution. (Graphic: Business Wire)

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

PR Newswire associated0

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

Business Wire embedded0

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Novotech is a Great Place to Work Certified in the USA (Graphic: Business Wire)

Novotech Earns Great Place to Work® Certification in the United States

PR Newswire associated0

TraceLink Releases Opus Solution Environment, the First No-Code Environment for Visually Building Multi-Enterprise Supply Chain Solutions

Rejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest Clinical Updates

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

PR Newswire associated0

Advanced Method for Predicting Response to Midostaurin plus Chemotherapy in Acute Myeloid Leukaemia Greatly Outperforms Current Companion Diagnostic

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

PR Newswire associated0

Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology

TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide